When was rosuvastatin discovered

Lancet , — Circulation , — Watanabe, M. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxyheptonates, a novel series of HMG-CoA reductase inhibitors. Jones, P. Statin therapies for elevated lipid levels compared across dose ranges to rosuvastatin: low-density lipoprotein cholesterol and high density lipoprotein cholesterol results.

Earl, J. Download references. You can also search for this author in PubMed Google Scholar. Correspondence to Jeremy Quirk. Reprints and Permissions. Quirk, J. Tags: rosuvastatin , Statin. Copyright , Discovery Medicine. All Rights Reserved. Article Published in the Author Account of. Close Social Bookmarks. Facebook Twitter Google Bookmarks. Close E-mail. Close Subscribers please log in below to access PDF reprints.

Email: Password: Click here if you lost your password or simply need a new one. Nawrocki, J. Arteriosclerosis, Thrombosis, and Vascular Biology, 15 5 , — Ohfuji, K. Pharmacological action and clinical effects of the new HMG-CoA reductase inhibitor rosuvastatin calcium crestol. Japanese Pharmacology Journal, , — Roth, B.

Journal of Medicinal Chemistry, 34 1 , — Shook, R. Miracle medicines: Seven lifesaving drugs and the people who created them. Portfolio Hardcover. Watanabe, M. Synthesis and biological activity of methanesulfonamide primide- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxyheptenoates, a novel series of HMG-CoA reductase inhibitors.

Yamamoto, A. International Journal of Clinical Practice, 59 2 , — CrossRef Mukhtar, R. Arteriosclerosis, Thrombosis, and Vascular Biology, 15 5 , — CrossRef Nawrocki, J. Pharmacological action and clinical effects of the new HMG-CoA reductase inhibitor rosuvastatin calcium crestol. Japanese Pharmacology Journal, , — Ohfuji, K. Journal of Medicinal Chemistry, 34 1 , — CrossRef Roth, B. Miracle medicines: Seven lifesaving drugs and the people who created them.

Portfolio Hardcover. Shook, R. Synthesis and biological activity of methanesulfonamide primide- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxyheptenoates, a novel series of HMG-CoA reductase inhibitors.